latest update:
[TrialBase DB]

trial summary · NCT07748624

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period

Trial record from the TrialBase DB dataset, status RECRUITING, condition VEXAS Syndrome, sponsored by Novartis Pharmaceuticals. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07748624phase PHASE2enrollment 120start 2026-10-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.

Source record: https://clinicaltrials.gov/study/NCT07748624

Facts

registry idNCT07748624
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionVEXAS Syndrome
sponsorNovartis Pharmaceuticals
sponsor classINDUSTRY
enrollment120
start date2026-10-30
primary completion2028-12-26
completion2031-04-15
results postednot reported

Conditions

  • VEXAS Syndrome

Interventions

  • Arumakimig
  • Placebo
  • Oral glucocorticoids

Countries

  • Japan

Intervention types: DRUG

Work with this record